These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 21536664

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.
    World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [Abstract] [Full Text] [Related]

  • 6. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.
    BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [Abstract] [Full Text] [Related]

  • 9. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, Dimopoulos M, Papazisis K.
    Med Oncol; 2012 Jun; 29(2):750-4. PubMed ID: 21279702
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
    Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.
    Cancer; 2009 Jan 01; 115(1):61-7. PubMed ID: 19051290
    [Abstract] [Full Text] [Related]

  • 14. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.
    BJU Int; 2012 Sep 01; 110(5):692-8. PubMed ID: 22364110
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, Czech Renal Cancer Cooperative Group.
    Ann Oncol; 2012 Dec 01; 23(12):3137-3143. PubMed ID: 22700990
    [Abstract] [Full Text] [Related]

  • 17. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 01; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 19. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
    Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C, Siciliano RD, Stoll S, Knuth A, Buchler T, Porta C, Renner C, Samaras P.
    Oncology; 2012 May 23; 82(6):333-40. PubMed ID: 22677881
    [Abstract] [Full Text] [Related]

  • 20. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
    Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B.
    Med Oncol; 2012 Dec 23; 29(5):3321-4. PubMed ID: 22752573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.